Clinical proof-of-concept study with MSDC-0160, a ... - PubMed
(also known as Mitoglitazone) is an investigational drug originally developed to treat Type 2 diabetes. It is currently being explored for its potential to treat neurodegenerative diseases like Parkinson’s and Alzheimer’s. msdc 0160 buy
: Successfully completed Phase 2b trials where it lowered HbA1c levels similarly to pioglitazone (Actos) but with 50% less fluid retention. Clinical proof-of-concept study with MSDC-0160, a